DISCLAIMER: This product is strictly for research use only. It is meant solely for laboratory testing and in vitro studies-not for use in or on humans or animals. All details provided on this site are for educational purposes. It is illegal to introduce this substance into the body. Only licensed professionals should handle it. This item is not intended to be used as a drug, supplement, or cosmetic, and must not be misrepresented as such.
Retatrutide
Retatrutide is a next-generation investigational peptide being studied for its powerful effects on weight loss, metabolism, and overall metabolic health. It acts on three different hormone receptors (GLP-1, GIP, and glucagon), making it a triple agonist designed to help the body manage blood sugar, burn fat, and control appetite more effectively.
Variant: 10 mg
Quantity: 1
All peptides arrive in powdered form for stability
What is Retatrutide?
Retatrutide (LY3437943) is an investigational peptide developed by Eli Lilly that acts as a triple hormone receptor agonist, targeting GLP-1, GIP, and glucagon receptors. This next-generation compound is being studied for its powerful effects on weight loss, insulin sensitivity, and metabolic health. The unique triple-receptor mechanism may allow Retatrutide to outperform single or dual agonists like Semaglutide or Tirzepatide.
Potential Benefits Shown in Studies
- Rapid and sustained weight loss
- Reducing body fat and preserving muscle mass
- Controlling blood sugar and insulin resistance
- Decreasing appetite and food cravings
- Boosting metabolism and energy use
- Supporting liver health and fat reduction
- Improving markers of heart and metabolic function
Mechanisms of Action
Retatrutide combines three synergistic metabolic pathways:
- GLP-1 receptor activation: Lowers blood sugar, suppresses appetite, slows gastric emptying
- GIP receptor activation: Enhances insulin secretion and may protect beta cells
- Glucagon receptor activation: Increases energy expenditure and fat oxidation
This triple-agonist profile helps drive both caloric reduction and metabolic acceleration — leading to substantial fat loss and improved insulin control.
Molecular Structure of Retatrutide
Sequence
Retatrutide is a synthetic peptide with a modified sequence combining features of GLP-1, GIP, and glucagon analogues. (Exact amino acid sequence is proprietary and not publicly disclosed as of current publications.)
Molecular Properties
Retatrutide Research Highlights
In a 2023 Phase 2 trial published in The New England Journal of Medicine, participants receiving 12 mg of Retatrutide weekly lost an average of 24.2% of their body weight after 48 weeks — exceeding the average seen with Semaglutide or Tirzepatide.
In patients with type 2 diabetes, Retatrutide led to HbA1c reductions of up to 2.2% and improved fasting glucose. The effects were observed across all dosage levels.
The combination of enhanced fat loss and improved insulin sensitivity may reduce systemic inflammation, metabolic syndrome risk, and fatty liver disease progression.
Retatrutide is now in the TRIUMPH program, a set of global Phase 3 trials assessing its long-term safety and efficacy in obesity, cardiovascular disease, and prediabetes.
